Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company's lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. Show more

Location: Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium | Website: https://www.nyxoah.com | Industry: Medical Instruments & Supplies | Sector: Healthcare


Market Cap

220.8M

52 Wk Range

$5.55 - $11.87

Previous Close

$5.88

Open

$6.00

Volume

80,353

Day Range

$5.60 - $6.00

Enterprise Value

193.9M

Cash

42.99M

Avg Qtr Burn

-15.22M

Insider Ownership

41.73%

Institutional Own.

22.78%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date